Navigation Links
Senhwa Biosciences Raises $17M Series B
Date:12/12/2013

SAN DIEGO and NEW TAIPEI CITY, Taiwan, Dec. 12, 2013 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today. The Taiwan and San Diego, CA based company closed the round with participation from existing and new investors including H&Q Asia Pacific, Morningside and China Investment & Development Co., Ltd. Proceeds from the financing will be used to support the continuing development of its first-in-class anticancer agents CX-5461 and CX-4945 and take them through clinical proof-of-concept studies.

(Photo: http://photos.prnewswire.com/prnh/20131212/MN31456)

"Senhwa has made tremendous strides since its inception just one year ago. This round of funding will allow us to continue to advance and keeps us on course to open two new US-based Phase I and Phase II clinical trials during 2014," said Dr. Tai-Sen Soong, President of Senhwa Biosciences. "The level of commitment from new and existing investors reflects the quality of our assets, the confidence our investors have in our management team and it accelerates the development of Senhwa into a fully-fledged clinical development company."

Senhwa's lead anticancer compound for treating hematological malignancies is CX-5461, a p53 activating, Pol I inhibitor, currently in a Phase I clinical trial at the Peter MacCallum Cancer Centre in Melbourne, Australia. CX-5461 has a unique mechanism of action that enables selective activation of p53 in tumor cells but not in normal healthy ones, destroying malignant tissue while sparing the patient from the serious side effects associated with cancer therapies.

Senhwa's CK2 inhibitor, CX-4945, is being developed for combination treatment in solid tumors with the commonly used chemotherapy agents gemcitabine and cisplatin. Pre-clinically, combination of CX-4945 with these DNA damaging agents has been shown to act synergistically to enhance the efficacy of these anticancer treatments.

About Senhwa Biosciences

Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical proof-of-concept.

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and our service providers work from their bases in North America, Asia, Australia and Europe.For more information on Senhwa and its programs, please visit http://www.senhwabiosciences.com/.

Media Contact: Sean O'Brien, Senhwa Biosciences, 858-552-6808, sobrien@senhwabio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Senhwa Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants totaling ... as part of its prestigious Bayer Hemophilia Awards Program (BHAP). ... Philadelphia and Uniformed Services University of ... among the winners. Grant recipients were announced last night during ... (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/10/2017)... medical equipment and supply demand is forecast to reach ... Equipment & Supplies: United States , a report ... demand for medical services – driven in large part ... gains in disposable personal income – will boost sales ... also drive sales as providers and patients seek the ...
(Date:7/6/2017)... 2017 ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, ... on nutrition support. To celebrate its anniversary, ThriveRx recently launched ... fresh new look with improved organization to create the best user experience ... ... "We,ve made several great ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit against Dr. ... ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In Gegham ... Ale claims on its bottle that it is made from real ginger. , When ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched ... of acceptance to a residency in a United States hospital. Being accepted into ... U.S. , According to data released by the ECFMG®, every year, 50 percent ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce ... Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical ... dermatology, skin cancer , and more. She graduated from the University of Florida ...
(Date:7/21/2017)... ... 21, 2017 , ... How physicians and athletic trainers assess ... researchers presenting their work at the American Orthopaedic Society for Sports Medicine’s ... the patterns of change in concussion symptom presentation, diagnostic tools used and length ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
Breaking Medicine News(10 mins):